Clinical Trial Update: Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial investigating Radium Ra-223 dichloride with concurrent abiraterone acetate plus prednisone in symptomatic castration-resistant prostate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Radium Ra-223 Dichloride (radium-223 dichloride)

Snippet

Sponsor: Carolina Research Professionals, LLC | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-02-01